CoChat

Fluvastatin Causes NLRP3 Inflammasome-Mediated Adipose Insulin Resistance

Henriksbo, Brandyn D., Lau, Trevor C., Cavallari, Joseph F., Denou, Emmanuel, Chi, Wendy, Lally, James S., Crane, Justin D., Duggan, Brittany M., Foley, Kevin P., Fullerton, Morgan D., Tarnopolsky, Mark A., Steinberg, Gregory R., Schertzer, Jonathan D. · 2014 · Diabetes
Cited by 139

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Statins reduce lipid levels and are widely prescribed. Statins have been associated with an increased incidence of type 2 diabetes, but the mechanisms are unclear. Activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3)/caspase-1 inflammasome, promotes insulin resistance, a precursor of type 2 diabetes. We showed that four different statins increased interleukin-1β (IL-1β) secretion from macrophages, which is characteristic of NLRP3 inflammasome activation. This effect was dose dependent, absent in NLRP3−/− mice, and prevented by caspase-1 inhibition or the diabetes drug glyburide. Long-term fluvastatin treatment of obese mice impaired insulin-stimulated glucose uptake in adipose tissue. Fluvastatin-induced activation of the NLRP3/caspase-1 pathway was required for the development of insulin resistance in adipose tissue explants, an effect also prevented by glyburide. Fluvastatin impaired insulin signaling in lipopolysaccharide-primed 3T3-L1 adipocytes, an effect associated with increased caspase-1 activity, but not IL-1β secretion. Our results define an NLRP3/caspase-1–mediated mechanism of statin-induced insulin resistance in adipose tissue and adipocytes, which may be a contributing factor to statin-induced development of type 2 diabetes. These results warrant scrutiny of insulin sensitivity during statin use and suggest that combination therapies with glyburide, or other inhibitors of the NLRP3 inflammasome, may be effective in preventing the adverse effects of statins.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db13-1398

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 139

Metadata

Authors
Henriksbo, B. D., Lau, T. C., Cavallari, J. F., Denou, E., Chi, W., Lally, J. S., Crane, J. D., Duggan, B. M., Foley, K. P., Fullerton, M. D., Tarnopolsky, M. A., Steinberg, G. R., & Schertzer, J. D.
Venue
Diabetes
Published
2014-10-13
Volume
63
Issue
11
Pages
3742-3747
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2138175677
Cited by
139
References
6
FWCI
5.60
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fluvastatin Causes NLRP3 Inflammasome-Mediated Adipose Insulin Resistance. https://app.cochat.ai/papers/10.2337/db13-1398
The paper
Henriksbo, B. D., Lau, T. C., Cavallari, J. F., Denou, E., Chi, W., Lally, J. S., Crane, J. D., Duggan, B. M., Foley, K. P., Fullerton, M. D., Tarnopolsky, M. A., Steinberg, G. R., & Schertzer, J. D. (2014). Fluvastatin Causes NLRP3 Inflammasome-Mediated Adipose Insulin Resistance. Diabetes. https://doi.org/10.2337/db13-1398

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.